Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 March 2023.
Highlights for the quarter included:
-
1st patient dosed in clinical trial assessing CHM 0201 in combination with Vactosertib
-
3rd dose cohort in CHM 1101 Phase 1A completed with no dose limiting toxicities
-
Fourth dose cohort in CHM 1101 Phase 1A initiated with first patient treated
-
Viral vector manufacturing completed to support initiation of Phase 1 trial for CHM 2101
-
Positive feedback from US FDA at pre-IND meeting for CHM 2101
-
CHM 1101 abstract to be presented at ASCO 2023
-
Chimeric presents CAR T educational webinar in addition to virtual healthcare investor event
-
R&D tax incentive refund received
For more information, download the attached PDF.
Download this document
